



Basic science research article

COL6A1 related muscular dystrophy in Landseer dogs – a canine model for Ullrich congenital muscular dystrophy

Jan Brands, DVM,^{1*} Frank Steffen, DVM,² Jochen Spennes, DVM,³ Tosso Leeb, PhD,⁴ and Thomas Bilzer, DVM¹

¹ Institute of Neuropathology, University Hospital Düsseldorf, Moorenstrasse 5, 40225 Düsseldorf, Germany

² Neurology Service, Department of Small Animals, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 260, 8050 Zurich, Switzerland

³ Veterinary clinic Kaiserberg, Wintgensstrasse 81-83, 47058 Duisburg, Germany

⁴ Institute of Genetics, Vetsuisse Faculty, University of Bern, Bremgartenstrasse 109a, 3001 Bern, Switzerland

Acknowledgments

The authors are grateful to the referring veterinarians, the Tierärztliche Praxis am Loh GmbH (Ennepetal, Germany) and also to all dog owners and breeders who donated samples and shared pedigree data of their dogs. Special thank goes to Dr. Armin Zaisser for helping in the preparation of this study.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the [Version of Record](#). Please cite this article as doi: [10.1002/mus.27162](https://doi.org/10.1002/mus.27162)

This article is protected by copyright. All rights reserved.

Accepted Article

COL6A1 muscular dystrophy in Landseer dogs

*Corresponding author; e-mail: Janbrands@gmx.de (JB)

Running title

COL6A1 muscular dystrophy in Landseer dogs

Ethical publication statement

We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Disclosure of conflicts of interest

None of the authors has any conflict of interest to disclose.

COL6A1 related muscular dystrophy in Landseer dogs – a canine model for Ullrich congenital muscular dystrophy

Abstract

Introduction

Collagen VI related myopathies are congenital diseases of variable phenotype. The severe phenotype is referred to as Ullrich congenital muscular dystrophy. In this

COL6A1 muscular dystrophy in Landseer dogs

study, we describe analogous clinical signs and histopathological alterations in Landseer dogs.

Materials

We collected clinical data from 2 affected dogs and investigated the neuromuscular changes in 5 dogs from 2 different litters with immunohistochemistry and immunofluorescence. All affected dogs were homozygous for the p.Glu97* nonsense variant in the *COL6A1* gene encoding the alpha-1 chain of collagen VI.

Results

Muscle biopsies revealed alterations similar to those in human patients with Ullrich congenital muscular dystrophy including the virtual absence of collagen VI in skeletal muscles.

Discussion

The clinical and pathological characterization of the affected Landseer dogs enhances the value of this animal model for human Ullrich congenital muscular dystrophy.

Key words

COL6A1 muscular dystrophy in Landseer dogs

collagen VI; animal model; Ullrich congenital muscular dystrophy; canis lupus familiaris

Introduction

Human collagen VI related congenital myopathies are commonly described as two different phenotypic forms, a mild form referred to as Bethlem myopathy (BM) and a severe form referred to as Ullrich congenital muscular dystrophy (UCMD).^{1,2,3,4} They are caused by genetic variants in *COL6A1*, *COL6A2* or *COL6A3*, encoding the three subunits of collagen VI.^{5,6} Depending on the specific genetic variant, the severity of

COL6A1 muscular dystrophy in Landseer dogs

the phenotypes and the mode of inheritance can vary.^{7,8} A complete list of all known functional human variants in the collagen VI genes can be found on the Leiden Muscular Dystrophy pages.⁹

Typical clinical signs of patients with UCMD are kyphosis, torticollis, hip dislocation, patella contracture, proximal contractures, distal joint hyperlaxity and protruding calcanei.¹⁰ From the muscular dystrophies described in dogs^{11,12} collagen VI related myopathies in Labrador Retriever dogs show an intermediate severity in comparison to human patients with BM or UCMD. The genetic origin has been identified as 2 different variants in *COL6A3*. In one, Labrador Retriever dog collagen VI was nearly absent in the sarcolemma but normal in the endomysium, while the other completely lacked collagen VI in muscle tissue.^{13, 14}

Dogs have been recognised as providing useful models for human hereditary diseases¹⁵ and analogous diseases with similar phenotypes have also been described in *DMD* mutant dogs.¹⁶⁻¹⁹ Golden Retrievers carrying a *DMD* gene variant represent a valuable and widely used animal model for human Duchenne muscular dystrophy.²⁰ The canine model is of particular relevance because mice harbouring nonsense variants in the *DMD* gene do not display the severe phenotypes seen in humans and dogs.²¹⁻²³

We previously identified the presumed causative genetic defect in the *COL6A1* gene in Landseer dogs with a severe muscular dystrophy and provided an initial limited characterization of the clinical and histopathological phenotype. All affected dogs were homozygous for the mutant allele at a nonsense variant in *COL6A1*, p.Glu97*.²⁴

In this report, we present the long-term follow up characterization of the clinical and pathological phenotype of the Landseer dogs and a comparative analysis between dogs and humans in order to provide the Landseer dog as a useful model for human UCMD.

Materials and Methods

Ethics statement

All dogs in this study were examined with the consent of their owners. The collection of blood samples was approved by the Cantonal Committee For Animal Experiments (Canton of Bern; permit 23/10). Clinical examinations of the affected Landseer dogs and their littermates including the collection of muscle biopsies were performed in the course of standard veterinary diagnostics, with the consent and on behalf of the dog owners. The clinical examinations therefore did not constitute an animal experiment in the legal sense and did not require ethical approval.

Histopathological examinations

A complete list of all muscles biopsied is summarized in Supplemental Table 1. All biopsies were measured, catalogued, subsequently frozen at -135°C in isopentane and stored at -80°C for further analysis. Additionally, the quadriceps femoris biopsy of one affected dog (S3) was fixed in 4% formaldehyde and embedded in paraffin. The frozen biopsies were cut into 7 µm sections at -20°C using a cryostat (CM 1900, Leica Biosystems, Wetzlar, Germany). Samples were stained using haematoxylin and eosin (H&E), modified Gomori trichrome according to Engel & Cunningham (GT), oil red O and histochemically with acidic phosphatase, adenosine triphosphatase (ATPase) at pH 4.4 and pH 9.4 and nicotinamide adenine dinucleotide-tetrazolium reductase (NADH-TR).

Additional immunohistochemical stains for collagen IV (1:50, CIV22, Dako), collagen VI (1:1000, ab6588, Abcam; reacting with type specific epitopes), dystrophin 1 (1:100, NCL-DYS1, Novocastra), dystrophin 2 (1:100, NCL-DYS2, Novocastra), beta sarcoglycan (1:50, NCL-b-SARC, Novocastra), gamma sarcoglycan (1:100, NCL-g-SARC, Novocastra), spectrin 1 (1:100, NCL-SPEC1, Novocastra) and emerin (1:50, NCL-EMERIN, Novocastra) were done. The anti-collagen VI antibody ab6588 is a rabbit polyclonal antibody that was raised against human native collagen alpha-1(VI).

All sections were examined under a light microscope (Leica DM 5000 B, Leica Microsystems, Wetzlar, Germany) at 100x, 400x and 1000x magnification. The illustrated pictures were taken with a light microscope camera (DFC 290, Leica Microsystems, Wetzlar, Germany).

Supplemental samples were incubated with antibodies for immunofluorescent labeling collagen IV (CIV22, Dako) and collagen VI (ab6588, Abcam; reacting with type specific epitopes). These were examined under a fluorescence microscope (Axio Imager 2, Carl Zeiss Microscopy, Wetzlar, Germany) in 100x, 400x and 1000x magnification.

The photomicrographs were taken with a light microscope camera (AxioCam MRm, Carl Zeiss Microscopy, Wetzlar, Germany).

Results

Clinical presentation

We obtained clinical data and blood test results from juvenile Landseer dogs of 2 different litters. Two affected dogs were born in Germany (G1, G2; both females and the only affected from a litter of 9; 2 littermates died within the first 24 hours) and 4 in Switzerland (S1-S4; 2 males and 2 females from a litter of 7). The 2 litters had

several common ancestors (Figure 1). Genetic testing of blood samples revealed a homozygous mutant at a nonsense variant, p.Glu97*, in the *COL6A1* gene (Supplementary Figure 1). Affected dogs had severe signs of general muscle weakness and atrophy from the first weeks of life that had reached a severe level at the time of presentation. One affected male (S1) with profound clinical signs of muscle weakness was euthanised at an early age with no further investigation. Muscle atrophy was most striking in G2, a dog that achieved only 61 % of the typical weight of a full grown female Landseer dog.²⁴ Postural reactions, tendon reflexes (exception: reduced in G1), sensation and cranial nerve examination (exception: reduced gag reflex and megaesophagus in S4) were normal. A generalised neuromuscular disease with predominant muscle dysfunction was evident so that lesion localization and muscle biopsies were obtained for further investigation. All affected dogs had to be euthanised at the age of 1 to 15 months due to the severity of their clinical signs and poor quality of life. Detailed clinical data and relevant blood test results of all 6 cases and the unaffected littermate are summarized in Table 1.

Histopathological findings

Individual pathologic lesions are summarized in Supplementary Table 1. H&E and GT staining revealed a severely abnormal overall histologic morphology (Figure 2 C-F).

In comparison to the unaffected sibling (Figure 2 A+B) the total amount of muscle fibres was markedly reduced. Reaction for acid phosphatase showed an increase of activity indicating degeneration and necrosis within muscle fibres. Oil red O staining indicated muscle inactivity and further highlighted the amount of adipose tissue. The alterations were more prominent in proximal than in distal muscles (S3, S4).

Staining for the oxidative enzymes ATPase and NADH-TR showed an indistinct distribution of type 1 and 2 fibres with no predominance of either type.

While immunohistochemical staining for dystrophin 1 & 2, beta sarcoglycan, gamma sarcoglycan, spectrin 1 and emerin were normal, staining for collagen VI revealed an absence in both sarcolemma and endomysium (Figure 3 B). Further immunofluorescence investigations for collagen VI showed similar results (Figure 4 E+H).

Discussion

Muscle samples from affected dogs showed alterations commonly seen in muscular dystrophies. The lesions closely resembled those of human UCMD.^{26,27} Varying alterations demonstrate different stages of muscular destruction with compensatory hypertrophy and progressive replacement of lost fibres by connective and adipose tissue. These histopathological findings are also a common feature of the severe

COL6A1 muscular dystrophy in Landseer dogs

Duchenne muscular dystrophy of Golden Retrievers with a genetic defect in the X-linked *DMD* gene coding for dystrophin.²¹⁻²³ However, myofiber necrosis in the *COL6A1*^{-/-} Landseer dogs was generally less prominent and the mitochondria had no substantial alterations such as ragged red fibres.²⁰ CK elevation was only mild to moderate, similar to human UCMD patients,⁴ while CK in the affected Golden Retrievers is highly increased and a helpful tool in diagnosis.²² A comparison of the clinical and histopathological hallmarks between UCMD, BM, *Col6a1*^{-/-} knock out mice and the affected Landseer dogs is summarised in Table 2.

All muscle biopsies lacked antibody reaction to collagen VI in the sarcolemma and showed only weak immunofluorescence in the endomysium. A plausible explanation could be nonspecific reactions of the anti-collagen alpha-1(VI) antibodies to epitopes located on other extracellular collagen VI subunits that are not affected by the p.Glu97* nonsense variant in the *COL6A1* gene. Alternatively, it might result from cross reactions with other proteins or variability of the antibodies used.²⁸

Muscle atrophy and adipose tissue distribution in G2 was excessive and present in both superficial gluteus and semimembranosus muscle (Figure 3C). As the genetic diagnosis was not known during the course of the disease, most of the investigated dogs received only symptomatic support. Analogous therapy as in human patients could possibly slow down disease progression as seen in G2, which may have achieved the longest survival because the dog received the most aggressive

COL6A1 muscular dystrophy in Landseer dogs

symptomatic support (i.e. physiotherapy with use of an underwater treadmill) until the last possible point in time. We believe that the observed dramatic muscle atrophy and histopathologic picture of G2 represents the end stage of the disease. A canine muscular dystrophy with a comparable clinical picture and prominent histopathologic fatty change in distal muscle biopsies has been described in Rottweiler dogs. In contrast to the Landseer dogs that showed a proximal distribution, similar to humans with UCMD⁴, these dogs developed a distal myopathy caused by a presumed defect in the sarcolemmal transport of carnitine.²⁹

The complete lack of collagen VI and the severe clinical phenotype, resembling human patients with UCMD, also differentiates the affected *COL6A1*^{-/-} Landseer dogs from the 2 described Labrador Retriever dogs with variants in *COL6A3* that showed milder (“BM like”) phenotypes. One Labrador dog carried a recessive allele with a premature stop codon in a homozygous state (*COL6A3*:p.R1576*). Immunolabeling in this dog revealed a complete lack of collagen VI in skeletal muscles, while the other dog showed a sarcolemma specific collagen VI deficiency. The second dog carried a dominant allele in a heterozygous state leading to altered splicing (*COL6A3*:c.6210+1G>A).^{13,14} As in humans with collagen VI alterations, the clinical severity in dogs is most likely variable and dependent on the specific genetic variant. UCMD is the most severe phenotype with progressive weakness and muscle contractures. Affected patients lose the ability to walk within the first or second

COL6A1 muscular dystrophy in Landseer dogs

decade of life. BM has milder clinical signs and longer periods of unassisted ambulation.⁸

Col6a1^{-/-} knockout mice are an animal model for collagen VI related congenital muscular dystrophies/BM.³⁰ Although they do not express any residual collagen alpha-1(VI) chains, the mice lack the severe phenotype of UCMD. In contrast, the affected Landseer dogs showed a severe and clinically relevant phenotype, much closer to the human condition.

Electron microscopy of *Col6a1*^{-/-} knock out mice muscle cells showed mitochondrial tubular cristae, electron-dense inclusions, overt swelling and additional marked dilations of the sarcoplasmic reticulum. These alterations are due to mitochondrial dysfunction.³¹ Treatment with cyclosporine A leads to the inhibition of the mitochondrial permeability transition pore. In *Col6a1*^{-/-} mice this rescued the ultrastructural defects in muscle and markedly decreased the number of apoptotic nuclei *in vivo*.³² Mitochondrial defects can also be seen in human patients with genetic defects in *COL6A1* or *COL6A3* gene.³³ Consequently, further investigations of the Landseer UCMD should comprise electron microscopy, which was not possible in the present study because glutaraldehyde-fixed material was not available).

There is currently no cure for human patients with a collagen VI related congenital muscular dystrophy. Management consists of physiotherapy, orthopaedic treatment,

surgery and respiratory support.^{34,35} Six human patients were treated with cyclosporine A (3-5 mg/kg) over 1 to 3.2 years in an open trial study. Treatment corrected mitochondrial dysfunction, increased muscle regeneration and decreased the number of apoptotic nuclei. This resulted in improvement of muscle strength, but did not affect motor function or further deterioration of respiratory function.³⁵

In conclusion, we provide a refined clinical and histopathological description of a collagen VI related severe canine muscular dystrophy. The Landseer dogs carrying the *COL6A1* nonsense variant in a homozygous state could potentially be used in place of *Col6a1*^{-/-} knock out mice for final tests before human clinical trials of a novel therapy for human UCMD, as their clinical phenotype more closely resembles the human situation. A genetic test for the *COL6A1*:p.Glu97* nonsense variant in dogs is commercially available and can be used to establish a colony starting from heterozygote carriers (Figure 1).³⁶

Abbreviations:

ATPase	adenosine triphosphatase
BM	Bethlem myopathy
BMD	Becker muscular dystrophy

COL6A1 muscular dystrophy in Landseer dogs

CK	creatine kinase
<i>Col6a1</i>^{-/-}	mice with two null alleles in the <i>Col6a1</i> gene encoding collagen type VI alpha 1 chain
<i>COL6A1</i>^{-/-}	Landseer dogs with two null alleles in the <i>COL6A1</i> gene encoding collagen type VI alpha 1 chain
<i>COL6A1</i>	gene encoding collagen type VI alpha 1 chain
<i>COL6A2</i>	gene encoding collagen type VI alpha 2 chain
<i>COL6A3</i>	gene encoding collagen type VI alpha 3 chain
GT	modified Gomori trichrome according to Engel & Cunningham
G1	affected dog 1 from Germany
G2	affected dog 2 from Germany
H&E	haematoxylin and eosin
NADH-TR	nicotinamide adenine dinucleotide-tetrazolium reductase
S1	affected dog 1 from Switzerland
S2	affected dog 2 from Switzerland
S3	affected dog 3 from Switzerland

S4	affected dog 4 from Switzerland
S5	control dog from Switzerland
UCMD	Ullrich congenital muscular dystrophy

References

1. Ullrich O. Kongenitale, atonisch-sklerotische Muskeldystrophie, ein weiterer Typus der heredodegenerativen Erkrankungen des neuromuskulären Systems. Zeitschrift für die gesamte Neurologie und Psychiatrie 1930; **126**:171–201.
2. Ullrich O. Kongenitale, atonisch-sklerotische Muskeldystrophie. Monatsschr. Kinderheilkd. 1930; **47**:502–510.
3. Bethlem J, van Wijngaarden GK. Benign myopathy, with autosomal dominant inheritance. A report on three pedigrees. Brain 1976; **99**:91–100.
4. Flanigan KM. The muscular dystrophies. Semin. Neurol. 2012; **32**:255-263.

COL6A1 muscular dystrophy in Landseer dogs

5. Jöbsis GJ, Keizers H, Vreijling JP, de Visser M, Speer MC, Woltermann RA, *et al.* Type VI collagen mutations in Bethlem myopathy, an autosomal dominant myopathy with contractures. *Nat. Genet.* 1996; **14**:13-115.
6. Camacho Vanegas O, Bertini E, Zhang RZ, Petrini S, Minosse C, Sabatelli P, *et al.* Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI. *Proc. Natl. Acad. Sci. U. S. A.* 2001; **98**:7516-7521.
7. Allamand V, Briñas L, Richard P, Stojkovic T, Quijano-Roy S, Bonne G. ColVI myopathies: where do we stand, where do we go? *Skelet. Muscle* 2011; **1**:30.
8. Bönnemann CG. The collagen VI-related myopathies: muscle meets its matrix. *Nat. Rev. Neurol.* 2011; **7**:379-90.
9. <http://www.dmd.nl/>

10. Yonekawa T, Nishino I. Ullrich congenital muscular dystrophy: clinicopathological features, natural history and pathomechanism(s). *J. Neurol. Neurosurg. Psychiatry* 2015, **86**:280-287.
11. Shelton GD, Engvall E, Muscular dystrophies and other inherited myopathies. *Vet. Clin. North Am. Small Anim. Pract.* 2002; **32**:103-124.
12. Barth´el´emy I, Hitte C, Tiret L. The Dog Model in the Spotlight: Legacy of a Trustful Cooperation. *Neuromuscul Dis.* 2019; **6**:421-451.
13. Marioni-Henry K, Haworth P, Scott H, Witte P, Guo LT, Shelton GD. Sarcolemmal specific collagen VI deficient myopathy in a Labrador Retriever. *J. Vet. Intern. Med.* 2014; **28**:243–249.
14. Bolduc V, Minor KM, Hu Y, Kaur R, FriedenberG SG, van Buren S, *et al.* Pathogenic variants in *COL6A3* cause Ullrich-like congenital muscular dystrophy in young Labrador Retriever dogs. *Neuromul Disord.* 2020; **30**:360-367.

15. Shelton GD, Engvall E. Canine and feline models of human inherited muscle diseases. *Neuromuscul. Disord.* 2005; **15**:127-138.
16. Sharp NJ, Kornegay JN, Van Camp SD, Herbstreith MH, Secore SL, Kettle S, *et al.* An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. *Genomics* 1992; **13**:115–121.
17. Smith BF, Yue Y, Woods PR, Kornegay JN, Shin JH, Williams RR, *et al.* An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the corgi breed. *Lab Invest.* 2011; **91**:216–231.
18. Atencia-Fernandez S, Shiel RE, Mooney CT, Nolan CM. Muscular dystrophy in the Japanese Spitz: an inversion disrupts the DMD and RPGR genes. *Anim Genet.* 2015; **46**:175–184.
19. Jenkins CA, Forman OP. Identification of a novel frameshift mutation in the

COL6A1 muscular dystrophy in Landseer dogs

DMD gene as the cause of muscular dystrophy in a Norfolk terrier dog.

Canine Genet Epidemiol. 2015; **2**:7.

20. Kornegay JN. The golden retriever model of Duchenne muscular dystrophy.

Skelet Muscle 2017; **7**:9.

21. Cooper BJ, Winand NJ, Stedman H, Valentine BA, Hoffman EP, Kunkel LM, *et al.*

The homologue of the Duchenne locus is defective in X-linked muscular dystrophy in dogs. Nature 1988; **334**:154–156.

22. Valentine BA, Cooper BJ, de Lahunta A, O'Quinn R, Blue TJ. Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies. J. Neurol. Sci. 1988; **88**:69-81.

23. Valentine BA, Winand NJ, Pradhan D, Moise NS, de Lahunta A, Kornegay JN, *et al.* Canine X-linked muscular dystrophy as an animal model of Duchenne muscular dystrophy: a review. Am. J. Med. Genet. 1992; **42**:352-356.

24. Steffen F, Bilzer T, Brands J, Golini L, Jagannathan V, Wiedmer M, *et al.* A Nonsense Variant in *COL6A1* in Landseer Dogs with Muscular Dystrophy. *G3* (Bethesda) 2015; **5**:2611-2617.
25. <http://www.fci.be/Nomenclature/Standards/050g02-en.pdf>
26. Histological and Histochemical changes. In: Dubowitz V, Sewry CA, Oldfors A. *Muscle Biopsy: A Practical Approach*, 4th ed. London: Saunders Elsevier; 2013. p. 55–94.
27. Muscular dystrophies and allied disorders III: Congenital muscular dystrophies and associated disorders. In: Dubowitz V, Sewry CA, Oldfors A. *Muscle Biopsy: A Practical Approach*, 4th ed. London: Saunders Elsevier; 2013. p. 302–319.
28. Baker M. Reproducibility crisis: Blame it on the antibodies. *Nature* 2015; **521**:74-276.

29. Hanson SM, Smith MO, Walker TL, Shelton GD. Juvenile-onset distal myopathy in Rottweiler dogs. *J. Vet. Intern. Med.* 1998; **12**:103-108.
30. Bonaldo P, Braghetta P, Zanetti M, Piccolo S, Volpin D, Bressan GM. Collagen VI deficiency induces early onset myopathy in the mouse: an animal model for Bethlem myopathy. *Hum. Mol. Genet.* 1998; **7**:2135-2140.
31. Irwin WA, Bergamin N, Sabatelli P, Reggiani C, Megighian A, Merlini L, *et al.* Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency. *Nat. Genet.* 2003; **35**:367–371.
32. Angelin A, Tiepolo T, Sabatelli P, Grumati P, Bergamin N, Golfieri C, *et al.* Mitochondrial dysfunction the pathogenesis of Ullrich congenital muscular dystrophy and prospective therapy with cyclosporins. *Proc. Natl. Acad. Sci. U. S. A.* 2007; **104**:991–996.

33. Merlini L, Bernardi P. Therapy of Collagen VI-Related Myopathies (Bethlem and Ullrich). *Neurotherapeutics* 2008; **5**:613-618.
34. Wang CH, Dowling JJ, North K, Schroth MK, Sejersen T, Shapiro F, *et al.* Consensus statement on standard care of care for congenital myopathies. *J. Child. Neurol.* 2012; **27**:362-382.
35. Merlini L, Sabatelli P, Armaroli A, Gnudi S, Angelin A, Grumati P, *et al.* Cyclosporine A in Ullrich congenital muscular dystrophy: long-term results. *Oxid. Med. Cell Longev.* 2011; **2011**:139194.
36. <http://www.animalabs.com/shop/dogs/landseer-muscular-dystrophy-mdl/>

Figure 1

Pedigree of the investigated dogs.

COL6A1 muscular dystrophy in Landseer dogs

The six affected dogs (S1-S4, G1, G2) originated in two litters from Switzerland and Germany. The German litter on the right side is inbred to a great-great-grandfather shown at the top right of the pedigree. Three key ancestors marked with asterisks are shared by both litters. Genotypes at *COL6A1*:c.289G>T are indicated for those dogs from which a DNA sample was available.

Figure 2

Histopathology of quadriceps femoris biopsies.

(A+B) unaffected littermate at 4.5 months (S5); (C+D) affected female dog at 8 months (G1); (E+F) affected male dog at 4 months (S2). (A, C, E) H&E staining. (B, D, F) GT staining.

(A +B) Normal muscle histologic morphology without significant pathological changes. Muscle and fibre size configuration and variation, sarcolemma, nuclear structure and distribution as well as perimysial and endomysial connective tissue are of physiological appearance.

(C, D, E, F) Muscle fibres show an abnormal and inhomogeneous variation in size and configuration, indicating fibre hypertrophy and atrophy. The shape of most fibres is round instead of polygonal and distribution of enlarged and small fibres was random and diffuse, implying the cause of the alterations to be of myopathic origin.

COL6A1 muscular dystrophy in Landseer dogs

Additionally, occasional central nuclei (arrows) and basophilic regeneration are visible. Fibre loss is accompanied by remarkable excess and distortion of both perimysial (stars) and endomysial connective tissue combined with the abundance of adipose tissue.

(A, B, C, D) 1000x magnification, bar 20 μm . (E+F) 400x magnification, bar 50 μm .

Figure 3

Immunohistochemistry of quadriceps femoris biopsies for collagen VI and end stage disease picture of a superficial gluteus biopsy.

(A) Unaffected littermate at 4.5 months (S5); (B) affected female dog at 8 months (G1); (C+D) affected female dog at 15 months (G2).

(A +B) Immunostaining for collagen VI. Collagen VI (indicated by dark colour) is present in both sarcolemma and endomysium of the unaffected littermate (A) and absent in the affected dog (B).

(C+D) H&E stained end stage picture of the disease. Large amounts of pale necrotic fibres (arrows) and a “moth eaten” histologic appearance with excessive replacement by adipose tissue. The muscle biopsy is embedded in mounting medium (stars).

COL6A1 muscular dystrophy in Landseer dogs

(A) 1000x magnification, bar 20 μm ; (B) 400x magnification, bar 50 μm ; (C) 100x magnification, bar 200 μm . (D) 1000x magnification, bar 20 μm .

Figure 4

Double immunofluorescence of quadriceps femoris biopsies for collagen IV and VI.

(A-C) Unaffected littermate at 4.5 months (S5); (D-F) affected female dog at 8 months (G1); (G-I) affected male dog at 4 months (S2).

(A,D,G) Immunofluorescence for collagen IV (green colour). Collagen IV is present in all dogs.

(B,E,H) Immunofluorescence for collagen VI (red colour). Collagen VI is absent from the sarcolemma of the affected dogs. Small spots in the endomysium of the affected dogs probably represent unspecific epitopes not related to collagen alpha-1(VI) subunits.

(C,F,I) Merged images. Both collagen IV and VI are present in the unaffected littermate (yellow colour); the affected dogs show only small spots of yellow colour in the endomysium.

1000x magnification, bar 20 μm .

Table 1 Clinical data

Subject	G1 ^f	G2 ^f	S1 ^f	S2 ^f	S3 ^f	S4 ^f	S5 ^f
Gender	Female	Female	Male	Female	Male	Female	Female
Genotype at COL6A1:p.Glu97*	T/T	T/T	T/T	T/T	T/T	T/T	G/T
Age at onset	8 weeks	2-3 weeks	2-3 weeks	2-3 weeks	2-3 weeks	2-3 weeks	No onset
Clinical signs	8 weeks: plantigrade stance, simultaneous lifting of both hindlimbs while walking 7 months: non-ambulatory, elevated body temperature (39.6°C), highly prominent muscle atrophy with proximal dominance, thickend and	2-3 weeks: palmi- and plantigrade stance 4 weeks: reluctance to move 4 months: proximal joint contractures 5 months: generalised muscle atrophy with proximal dominance, unsecure hypometric gait with falling down	No further details were provided	4 months: prolonged sleeping episodes, reluctance to move, short strided gait, muscle atrophy, proximal joint contractures and pain on palpation	4 months: prolonged sleeping episodes, reluctance to move, short strided gait, muscle atrophy, proximal joint contractures and pain on palpation	4 months: non-ambulatory, elevated body temperature (39.6°C), highly prominent muscle atrophy, reduced gag reflex, megaoesophagus, aspiration pneumonia	No abnormal findings


	contracted joints, absent proprioceptive positioning	6.5-15 months: recurring joint swelling and continuous muscle atrophy 15 months: non- ambulatory					
Subject	G1[†]	G2[†]	S1[†]	S2[†]	S3[†]	S4[†]	S5[†]
CK[#]	1037 (IU/l)	Not tested	Not tested	935 (IU/l)	422 (IU/l)	1149 (IU/l)	297 (IU/l)
Reference value	49 – 146 (IU/l)			51 – 191 (IU/l)			
Weight at biopsy	20 kg	34 kg	Not measured	19 kg	15 kg	16 kg	27 kg
Age at euthanasia	8 months	15 months	4 weeks	5 months	5 months	5 months	Not euthanised







[†] German (G1+2) and Swiss dogs (S1-5); [#] creatine kinase





Table 2 Comparison of human, murine and Landseer dogs collagen VI related muscular dystrophies

Type of collagen VI related muscular dystrophy	Ullrich congenital muscular dystrophy	Bethlem Myopathy	<i>Col6a1</i> ^{-/-} knock out mice	Landseer dogs homozygous for p.Glu97* nonsense variant in <i>COL6A1</i>
Age at onset	At birth or within first weeks of life	Mainly adult life, can occur in childhood or congenital	No obvious phenotype	2-8 weeks
Clinical features	Severe progressive muscle weakness and hypotonia, hyperlaxity of distal and contractures of proximal joints, dislocation of hips, delayed ambulation (achieved in some but not all), round face with prominent ears, hyperkeratosis and abnormal scar formation, progressive respiratory insufficiency leading to respiratory failure, prominent calcanei, scoliosis, CK# normal or mildly elevated	Commonly long finger flexor and sometimes elbow and ankle contractures, mild progressive muscle weakness (proximal > distal), respiratory insufficiency may appear after 4th decade, CK# normal or mildly elevated	No obvious muscular phenotype, reduced skin tensile strength	Severe progressive muscle weakness and hypotonia, hyperlaxity of distal and contractures of proximal joints in some cases, later all cases with proximal and distal joint contractures, CK# mild to moderate elevated, non ambulatory at 4-15 months, megaesophagus and aspiration pneumonia in 1 case
Histopathologic lesions	Abnormal variation in fibre size, round fibre shape, fibre atrophy, internal nuclei, extensive amount of endomysial connective tissue, necrotic fibres, basophilic regenerating fibres, indistinct fibre type or predominance of type 1, immunolabeling: complete lack of collagen VI in skeletal muscles or just in the sarcolemma	Same changes as Ullrich congenital muscular dystrophy but less distinctive alterations, immunolabeling: often no reduction in collagen VI	General signs of myopathy: muscle necrosis and phagocytosis, pronounced variation in fibre diameter, hypercontracted and necrotic fibres, most frequent in Diaphragm (up to 20% fibres) but also in intercostal, external oblique, straight abdominal and medial femoral muscles, immunolabeling: complete lack of collagen VI in skeletal muscles	Abnormal variation in fibre size, round fibre shape, fibre atrophy, internal nuclei, extensive amount of endomysial connective tissue, necrotic fibres, basophilic regenerating fibres, indistinct fibre type or predominance of type 1, immunolabeling: complete lack of collagen VI in skeletal muscles

Creatine kinase







This article is protected by copyright. All rights reserved.

